
|Articles|January 29, 2021
The COVID-19 Pandemic Has Disrupted Cancer Trials
Author(s)Aislinn Antrim, Assistant Editor
Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trials.
Advertisement
Pharmacy Times® interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers and medical director at Ann B. Barshinger Cancer Institute, Penn Medicine in Lancaster PA about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trial.
The full conversation can be found in the video above.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
2
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
3
From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
4
FDA Grants Orphan Drug Designation to Zavabresib for the Treatment of Myelofibrosis
5





















